CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 26, 2006
Result type: Reports
Project Number: S0082
Product Line: Common Drug Review

Generic Name: Natalizumab

Brand Name: Tysabri

Manufacturer: Biogen Idec Canada Inc.

Indications: Multiple Sclerosis, relapsing-remitting

Submission Type: New

Project Status: Complete

Date Recommendation Issued: April 26, 2007

Recommendation Type: Do not list